Extracorporeal membrane oxygenation (ECMO) in pediatric congenital heart disease: a comprehensive review
Review published in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2025)
Abstract
BACKGROUND: Extracorporeal membrane oxygenation (ECMO), which provides life-saving assistance in severe cardiac and pulmonary failure cases, has emerged as an important technique in managing children with congenital heart disease (CHD). MAIN BODY: In this review, we discuss the evolution of ECMO over the years, its clinical uses, and the results in pediatric CHD. ECMO has been utilized as a bridge to recovery, in stabilizing an individual after surgery, and as a bridge to heart transplantation. Cannulation procedures that are adjusted according to the anatomy of an individual have improved outcomes, although bleeding and neurologic concerns remain a matter of concern. In addition, long-term neurodevelopmental disorders and renal failure are also among the alarming outcomes. The use of newer anticoagulant drugs like bivalirudin, which lowers the risk of bleeding, and genomic testing for personalized treatment are examples of recent developments. Furthermore, neuroprotective techniques such as erythropoietin and dexmedetomidine can also enhance the neurocognitive outcomes. Finally, improvements in monitoring systems and pump technology contribute to increased ECMO efficacy and safety. CONCLUSION: Despite these developments, ECMO's expense and restricted accessibility remain major obstacles, especially in areas with low resources. In this review, the advancements in ECMO technology and care are highlighted, and it also emphasizes future research to address the current challenges.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Extracorporeal membrane oxygenation (ECMO), which provides life-saving assistance in severe cardiac and pulmonary failure cases, has emerged as an important technique in managing children with congenital heart disease (CHD).
Por qué esto importa para la hirudoterapia
Esta revisión discute la oxigenación por membrana extracorpórea (ECMO) en cardiopatías congénitas pediátricas, abarcando su evolución, usos clínicos (puente a la recuperación, estabilización posquirúrgica, puente al trasplante), complicaciones tales como sangrado y complicaciones neurológicas y renales, y desarrollos recientes, incluidos anticoagulantes más nuevos como la bivalirudina, señalada por reducir el riesgo de sangrado, estrategias neuroprotectoras, y mejoras en monitorización y bombas. El resumen menciona la bivalirudina únicamente como uno de varios avances y no contiene ninguna mención a hirudina, sanguijuelas ni terapéuticos derivados de sanguijuelas. En consecuencia, no es posible establecer una conexión defendible con la hirudoterapia o el secretoma de la sanguijuela a partir de este resumen; no se establece relevancia para ASH.
Citación
Extracorporeal membrane oxygenation (ECMO) in pediatric congenital heart disease: a comprehensive review
Faheem MSB et al. · The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2025
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026